Jiangsu Sihuan Bioengineering Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.03%

Jiangsu Sihuan Bioengineering Co Ltd (000518) has an Asset Resilience Ratio of 0.03% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥147.93K
≈ $21.65K USD Cash + Short-term Investments

Total Assets

CN¥509.14 Million
≈ $74.50 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (1992–2024)

This chart shows how Jiangsu Sihuan Bioengineering Co Ltd's Asset Resilience Ratio has changed over time. Check 000518 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Jiangsu Sihuan Bioengineering Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Jiangsu Sihuan Bioengineering Co Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥147.93K 0.03%
Total Liquid Assets CN¥147.93K 0.03%

Asset Resilience Insights

  • Limited Liquidity: Jiangsu Sihuan Bioengineering Co Ltd maintains only 0.03% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Jiangsu Sihuan Bioengineering Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangsu Sihuan Bioengineering Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Sk Biopharmaceuticals Co Ltd
KO:326030
Biotechnology 0.14%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 57.90%
TELIX Pharmaceuticals Ltd
AU:TLX
Biotechnology 32.29%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Theravance Biopharma Inc
F:0TB
Biotechnology 37.29%

Annual Asset Resilience Ratio for Jiangsu Sihuan Bioengineering Co Ltd (1992–2024)

The table below shows the annual Asset Resilience Ratio data for Jiangsu Sihuan Bioengineering Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.03% CN¥171.37K
≈ $25.08K
CN¥567.40 Million
≈ $83.03 Million
+0.01pp
2023-12-31 0.02% CN¥136.22K
≈ $19.93K
CN¥660.98 Million
≈ $96.72 Million
0.00pp
2022-12-31 0.02% CN¥161.12K
≈ $23.58K
CN¥738.08 Million
≈ $108.00 Million
-0.01pp
2021-12-31 0.03% CN¥226.30K
≈ $33.11K
CN¥799.31 Million
≈ $116.96 Million
-0.09pp
1998-12-31 0.12% CN¥214.13K
≈ $31.33K
CN¥180.33 Million
≈ $26.39 Million
+0.06pp
1997-12-31 0.06% CN¥187.68K
≈ $27.46K
CN¥299.24 Million
≈ $43.79 Million
-0.44pp
1996-12-31 0.51% CN¥1.38 Million
≈ $202.45K
CN¥273.91 Million
≈ $40.08 Million
-2.03pp
1995-12-31 2.54% CN¥6.63 Million
≈ $970.41K
CN¥261.39 Million
≈ $38.25 Million
-0.98pp
1994-12-31 3.52% CN¥9.97 Million
≈ $1.46 Million
CN¥283.19 Million
≈ $41.44 Million
+2.97pp
1993-12-31 0.55% CN¥1.40 Million
≈ $204.93K
CN¥254.61 Million
≈ $37.26 Million
+0.45pp
1992-12-31 0.10% CN¥126.79K
≈ $18.55K
CN¥126.97 Million
≈ $18.58 Million
--
pp = percentage points

About Jiangsu Sihuan Bioengineering Co Ltd

SHE:000518 China Biotechnology
Market Cap
$580.03 Million
CN¥3.96 Billion CNY
Market Cap Rank
#11404 Global
#3174 in China
Share Price
CN¥3.85
Change (1 day)
+4.34%
52-Week Range
CN¥2.24 - CN¥4.54
All Time High
CN¥9.49
About

Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusheng and xindelusheng, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded … Read more